Hypertension & Heart Failure
Hypertension is one of the most important modifiable risk factors for cardiovascular disease, and metabolic disorders are major drivers of both hypertension and heart failure. IMACH addresses them as one continuum of cardiovascular protection.
From raised pressure to a failing heart — one continuum.
Hypertension frequently coexists with diabetes, obesity, insulin resistance, dyslipidaemia and chronic kidney disease. Together these conditions damage blood vessels, the heart, kidneys and brain. Optimal control requires accurate diagnosis, risk stratification, appropriate therapy and long-term monitoring.
Heart failure is increasingly recognised as a major complication of metabolic disease. Diabetes, obesity and insulin resistance contribute to structural and functional cardiac changes — including heart failure with preserved ejection fraction (HFpEF), which is closely linked to metabolic dysfunction.
Advances such as SGLT2 inhibitors and incretin-based therapies have opened new possibilities for preventing and managing heart failure in metabolic patients. IMACH promotes early recognition, risk assessment and integrated management across cardiology, nephrology and metabolic medicine.
Key areas of scientific focus
Hypertension & vascular health
- Hypertension in metabolic disorders
- Blood-pressure measurement, home and ambulatory monitoring
- Resistant hypertension
- Endothelial dysfunction and arterial stiffness
- Target-organ damage
- Hypertension in women, pregnancy and older adults
Heart failure
- Heart failure in diabetes and obesity
- HFpEF and its metabolic phenotype
- Diabetic cardiomyopathy
- Cardiorenal-metabolic interactions
- Biomarkers and early detection
- Guideline-directed medical therapy in metabolic patients
Integrated management
- Combination antihypertensive strategies
- SGLT2 inhibitors and incretin therapies for cardiac protection
- Integrated blood pressure, glucose and lipid control
- Lifestyle and sodium reduction
- Cardiac rehabilitation
- Remote monitoring and follow-up
Clinical challenges we address
Undiagnosed hypertension
Many people are unaware of raised blood pressure until damage has occurred.
Poor control rates
Even treated patients frequently remain above target.
Missed HFpEF
Heart failure with preserved ejection fraction is often attributed to obesity or age and left untreated.
Therapy underuse
Proven heart-failure therapies are not consistently prescribed.
Cardiorenal complexity
Overlapping heart and kidney disease complicates treatment.
Adherence
Multiple medicines and asymptomatic disease make adherence difficult.
Translating evidence into everyday care
IMACH programmes emphasise accurate blood-pressure measurement, simplified single-pill combination strategies, early recognition of heart failure and consistent use of organ-protective therapies.
Key stages addressed:
| Care stage | Focus for clinicians |
|---|---|
| Measure correctly | Validated devices, out-of-office readings, screening for secondary causes. |
| Assess organ damage | ECG, echocardiography, kidney function, albuminuria. |
| Treat | Lifestyle, combination therapy and metabolic organ-protective agents. |
| Detect heart failure early | Symptoms, natriuretic peptides and imaging in at-risk metabolic patients. |
| Follow up | Titration, home monitoring, rehabilitation and adherence support. |
IMACH programmes in this area
BP measurement & control workshops
Technique, home monitoring and treatment algorithms.
Resistant hypertension clinics (training)
Work-up and management of difficult cases.
Metabolic cardiology symposia
HFpEF, obesity and diabetic heart disease.
Cardiorenal-metabolic forums
Joint cardiology–nephrology–endocrinology discussions.
Heart failure therapy optimisation
Practical initiation and titration of guideline therapies.
Rehabilitation & lifestyle modules
Exercise, nutrition and self-care.
Who this area brings together
Preventing and managing hypertension and heart failure depends on coordinated care across cardiology, nephrology, endocrinology and primary care.
Questions we explore
- How can blood-pressure control rates be improved in metabolic patients?
- When should heart failure be suspected in diabetes and obesity?
- How should organ-protective therapies be sequenced?
- What is the best approach to resistant hypertension?
- How can remote monitoring support long-term care?
Frequently asked questions
Why are hypertension and heart failure grouped together?
Hypertension is one of the leading causes of heart failure, and both share metabolic drivers. Managing them together supports earlier prevention.
What is HFpEF?
Heart failure with preserved ejection fraction — a form of heart failure where the heart pumps normally but is stiff. It is strongly associated with obesity, diabetes and hypertension.
Does this area include pregnancy-related hypertension?
Yes, hypertension in pregnancy is covered here and in Women’s Metabolic Health.
This page is intended for healthcare professionals and is educational in nature. It does not constitute medical advice or treatment recommendations for individual patients. Clinical decisions should follow current guidelines, local regulations and individual patient assessment.
Contribute to hypertension and heart failure care at IMACH.
Join as a member, faculty or research collaborator in this therapy area.